Leerink lowered the firm’s price target on Inspire Medical to $203 from $205 and keeps a Market Perform rating on the shares following the company’s Q1 earnings. The firm notes the company posted a modest top-line beat, but the outperformance was driven entirely by Outside U.S. revenues, while U.S. revenue came in 1.4% below consensus. The company raised its FY24 revenue guidance and now expects GAAP profitability during FY24, but Leerink expects shares to be under pressure due to disappointing U.S. sales, and management disclosing that they will no longer be providing color on center or territory guidance metrics that help the Street calculate utilization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems Engages with Investors in Upcoming Meetings
- Inspire Medical Systems, Inc. Announces First Quarter 2024 Financial Results and Updates 2024 Outlook
- Inspire Medical Systems, Inc. to Present at the BofA Securities 2024 Health Care Conference
- Inspire Medical initiated with an Outperform at RBC Capital
- UBS remains bullish on Inspire Medical after Lilly’s OSA results
Questions or Comments about the article? Write to editor@tipranks.com